Published in Infect Immun on April 01, 1998
Virulence control in group A Streptococcus by a two-component gene regulatory system: global expression profiling and in vivo infection modeling. Proc Natl Acad Sci U S A (2002) 3.83
A response regulator that represses transcription of several virulence operons in the group A streptococcus. J Bacteriol (1999) 3.81
Discovery of a widely distributed toxin biosynthetic gene cluster. Proc Natl Acad Sci U S A (2008) 3.20
A two-component regulatory system, CsrR-CsrS, represses expression of three Streptococcus pyogenes virulence factors, hyaluronic acid capsule, streptolysin S, and pyrogenic exotoxin B. Infect Immun (1999) 3.15
Genetic locus for streptolysin S production by group A streptococcus. Infect Immun (2000) 2.52
Molecular genetic analysis of a group A Streptococcus operon encoding serum opacity factor and a novel fibronectin-binding protein, SfbX. J Bacteriol (2003) 2.38
Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood (2007) 2.20
Disease manifestations and pathogenic mechanisms of group a Streptococcus. Clin Microbiol Rev (2014) 2.20
Nonpolar inactivation of the hypervariable streptococcal inhibitor of complement gene (sic) in serotype M1 Streptococcus pyogenes significantly decreases mouse mucosal colonization. Infect Immun (2000) 2.19
Description of staphylococcus serine protease (ssp) operon in Staphylococcus aureus and nonpolar inactivation of sspA-encoded serine protease. Infect Immun (2001) 2.02
The RofA binding site in Streptococcus pyogenes is utilized in multiple transcriptional pathways. J Bacteriol (2000) 1.94
The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury. J Invest Dermatol (2008) 1.79
Rgg influences the expression of multiple regulatory loci to coregulate virulence factor expression in Streptococcus pyogenes. Infect Immun (2002) 1.78
Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. J Clin Invest (2007) 1.72
Thiazole/oxazole-modified microcins: complex natural products from ribosomal templates. Curr Opin Chem Biol (2011) 1.67
Analysis of the transcriptome of group A Streptococcus in mouse soft tissue infection. Am J Pathol (2006) 1.53
Identification of a streptolysin S-associated gene cluster and its role in the pathogenesis of Streptococcus iniae disease. Infect Immun (2002) 1.52
Structural and functional dissection of the heterocyclic peptide cytotoxin streptolysin S. J Biol Chem (2009) 1.50
Role of streptolysin O in a mouse model of invasive group A streptococcal disease. Infect Immun (2000) 1.45
Streptolysin S-like virulence factors: the continuing sagA. Nat Rev Microbiol (2011) 1.42
Identification of pel, a Streptococcus pyogenes locus that affects both surface and secreted proteins. J Bacteriol (1999) 1.39
A genome-wide analysis of small regulatory RNAs in the human pathogen group A Streptococcus. PLoS One (2009) 1.36
Generation and surface localization of intact M protein in Streptococcus pyogenes are dependent on sagA. Infect Immun (2001) 1.34
Cytotoxic effects of streptolysin o and streptolysin s enhance the virulence of poorly encapsulated group a streptococci. Infect Immun (2003) 1.34
Streptococcus iniae virulence is associated with a distinct genetic profile. Infect Immun (2001) 1.30
relA-Independent amino acid starvation response network of Streptococcus pyogenes. J Bacteriol (2001) 1.29
Expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection. Proc Natl Acad Sci U S A (2005) 1.26
Peptide pheromone signaling in Streptococcus and Enterococcus. FEMS Microbiol Rev (2013) 1.25
Streptolysin S inhibits neutrophil recruitment during the early stages of Streptococcus pyogenes infection. Infect Immun (2009) 1.20
Complete genome sequencing and analysis of a Lancefield group G Streptococcus dysgalactiae subsp. equisimilis strain causing streptococcal toxic shock syndrome (STSS). BMC Genomics (2011) 1.19
Genome-wide identification of genes required for fitness of group A Streptococcus in human blood. Infect Immun (2013) 1.18
Contribution of CsrR-regulated virulence factors to the progress and outcome of murine skin infections by Streptococcus pyogenes. Infect Immun (2004) 1.16
Streptolysin S contributes to group A streptococcal translocation across an epithelial barrier. J Biol Chem (2010) 1.16
Specialized metabolites from the microbiome in health and disease. Cell Metab (2014) 1.12
Effects of oligopeptide permease in group a streptococcal infection. Infect Immun (2005) 1.11
Intracellular survival of Streptococcus pyogenes in polymorphonuclear cells results in increased bacterial virulence. Infect Immun (2003) 1.08
Genetic characterization and virulence role of the RALP3/LSA locus upstream of the streptolysin s operon in invasive M1T1 Group A Streptococcus. J Bacteriol (2006) 1.03
Combined contributions of streptolysin O and streptolysin S to virulence of serotype M5 Streptococcus pyogenes strain Manfredo. Infect Immun (2003) 1.02
Production of stabilized virulence factor-negative variants by group A streptococci during stationary phase. Infect Immun (1998) 1.00
Identification of group A Streptococcus antigenic determinants upregulated in vivo. Infect Immun (2005) 0.95
Mouse skin passage of a Streptococcus pyogenes Tn917 mutant of sagA/pel restores virulence, beta-hemolysis and sagA/pel expression without altering the position or sequence of the transposon. BMC Microbiol (2001) 0.95
Identification of novel growth phase- and media-dependent small non-coding RNAs in Streptococcus pyogenes M49 using intergenic tiling arrays. BMC Genomics (2012) 0.91
Virulence gene pool detected in bovine group C Streptococcus dysgalactiae subsp. dysgalactiae isolates by use of a group A S. pyogenes virulence microarray. J Clin Microbiol (2011) 0.91
Comparative genomics of Brachyspira pilosicoli strains: genome rearrangements, reductions and correlation of genetic compliment with phenotypic diversity. BMC Genomics (2012) 0.91
Generation of single-copy transposon insertions in Clostridium perfringens by electroporation of phage mu DNA transposition complexes. Appl Environ Microbiol (2009) 0.90
Synergistic effects of streptolysin S and streptococcal pyrogenic exotoxin B on the mouse model of group A streptococcal infection. Med Microbiol Immunol (2012) 0.89
Novel regulatory small RNAs in Streptococcus pyogenes. PLoS One (2013) 0.89
Role for sagA and siaA in quorum sensing and iron regulation in Streptococcus pyogenes. Infect Immun (2007) 0.88
Antibodies against a synthetic peptide of SagA neutralize the cytolytic activity of streptolysin S from group A streptococci. Infect Immun (2002) 0.88
Fatal case of sepsis caused by a non-haemolytic strain of Streptococcus pyogenes. J Clin Pathol (2007) 0.84
The sagA/pel locus does not regulate the expression of the M protein of the M1T1 lineage of group A Streptococcus. Virulence (2013) 0.83
HIV protease inhibitors block streptolysin S production. ACS Chem Biol (2015) 0.83
Hyaluronan breakdown contributes to immune defense against group A Streptococcus. J Biol Chem (2014) 0.80
YcaO-Dependent Posttranslational Amide Activation: Biosynthesis, Structure, and Function. Chem Rev (2017) 0.79
Inflammasome/IL-1β Responses to Streptococcal Pathogens. Front Immunol (2015) 0.78
Streptolysin S of Streptococcus anginosus exhibits broad-range hemolytic activity. Med Microbiol Immunol (2014) 0.78
The Mechanisms of Virulence Regulation by Small Noncoding RNAs in Low GC Gram-Positive Pathogens. Int J Mol Sci (2015) 0.75
Severe soft tissue infection caused by a non-beta-hemolytic Streptococcus pyogenes strain harboring a premature stop mutation in the sagC gene. J Clin Microbiol (2013) 0.75
Listeriolysin S Is a Streptolysin S-Like Virulence Factor That Targets Exclusively Prokaryotic Cells In Vivo. MBio (2017) 0.75
Inhibitory role of acyl homoserine lactones in hemolytic activity and viability of Streptococcus pyogenes M6 S165. Sci Rep (2017) 0.75
Opacification Domain of Serum Opacity Factor Inhibits Beta-Hemolysis and Contributes to Virulence of Streptococcus pyogenes. mSphere (2017) 0.75
Hypothesis: is a failure to prevent bacteriolysis and the synergy among microbial and host-derived pro-inflammatory agonists the main contributory factors to the pathogenesis of post-infectious sequelae? Inflammation (2001) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Regeneration of insertionally inactivated streptococcal DNA fragments after excision of transposon Tn916 in Escherichia coli: strategy for targeting and cloning of genes from gram-positive bacteria. J Bacteriol (1984) 6.82
A transposon in Streptococcus faecalis with fertility properties. Nature (1982) 5.65
A new modification of the carbazole analysis: application to heteropolysaccharides. Anal Biochem (1968) 5.56
Streptococcal toxins (streptolysin O, streptolysin S, erythrogenic toxin). Pharmacol Ther (1980) 4.08
Size variation of the M protein in group A streptococci. J Exp Med (1985) 3.45
Murine model of cutaneous infection with gram-positive cocci. Infect Immun (1992) 2.92
Geographic and temporal distribution and molecular characterization of two highly pathogenic clones of Streptococcus pyogenes expressing allelic variants of pyrogenic exotoxin A (Scarlet fever toxin). J Infect Dis (1993) 2.84
C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect Immun (1996) 2.77
Purification and characterization of group A streptococcal pyrogenic exotoxin type C. Infect Immun (1977) 2.59
Outbreak of group A streptococcus septicemia in children. Clinical, epidemiologic, and microbiological correlates. JAMA (1991) 2.27
Insertional inactivation of streptolysin S expression in Streptococcus pyogenes. J Bacteriol (1983) 2.13
Biochemical studies on streptolysin S' formed in the presence of yeast ribonucleic acid. I. The purification and some properties of the toxin. J Biochem (1963) 2.02
THE TOXIC PROPERTIES OF SERUM EXTRACTS OF HEMOLYTIC STREPTOCOCCI. J Exp Med (1934) 1.98
In vivo Streptococcus pyogenes C5a peptidase activity: analysis using transposon- and nitrosoguanidine-induced mutants. J Infect Dis (1987) 1.88
Molecular characterization of a locus required for hyaluronic acid capsule production in group A streptococci. J Exp Med (1992) 1.39
Tn916 target DNA sequences bind the C-terminal domain of integrase protein with different affinities that correlate with transposon insertion frequency. J Bacteriol (1995) 1.36
Partial inverse PCR: a technique for cloning flanking sequences. Biotechniques (1997) 1.28
Hemolytic mutants of group A Streptococcus pyogenes. J Clin Microbiol (1978) 1.23
Experimental staphylococcal infections in newborn mice: inhibition of weight gain as an index of virulence. J Med Microbiol (1980) 1.19
Streptolysin S: improved purification and characterization. Arch Biochem Biophys (1978) 1.16
The Serological Classification of Streptococcus pyogenes. J Hyg (Lond) (1934) 1.01
Purification and characterization of a peptide essential for formation of streptolysin S by Streptococcus pyogenes. Infect Immun (1992) 0.86
Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus. Science (1993) 10.09
Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med (1999) 10.06
Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med (1996) 8.41
Emergence of vancomycin-resistant enterococci in New York City. Lancet (1993) 7.37
Evasion of human innate and acquired immunity by a bacterial homolog of CD11b that inhibits opsonophagocytosis. Nat Med (2001) 4.09
Methicillin-resistant Staphylococcus aureus in horses and horse personnel, 2000-2002. Emerg Infect Dis (2005) 3.54
A clinical score to reduce unnecessary antibiotic use in patients with sore throat. CMAJ (1998) 3.46
The validity of a sore throat score in family practice. CMAJ (2000) 3.34
Detection of vancomycin resistance in Enterococcus species. J Clin Microbiol (1992) 3.30
Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 3.19
A two-component regulatory system, CsrR-CsrS, represses expression of three Streptococcus pyogenes virulence factors, hyaluronic acid capsule, streptolysin S, and pyrogenic exotoxin B. Infect Immun (1999) 3.15
Geographic and temporal distribution and molecular characterization of two highly pathogenic clones of Streptococcus pyogenes expressing allelic variants of pyrogenic exotoxin A (Scarlet fever toxin). J Infect Dis (1993) 2.84
Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis (1999) 2.69
Invasive infections due to a fish pathogen, Streptococcus iniae. S. iniae Study Group. N Engl J Med (1997) 2.60
Typing of Campylobacter pylori by bacterial DNA restriction endonuclease analysis and determination of plasmid profile. J Clin Microbiol (1990) 2.53
Genetic locus for streptolysin S production by group A streptococcus. Infect Immun (2000) 2.52
Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect Immun (2000) 2.34
Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada. Antimicrob Agents Chemother (2001) 2.30
Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal M1T1 isolates recovered from invasive group A streptococcal infection cases. Infect Immun (2000) 2.24
Reproducibility of interpretation of Gram-stained vaginal smears for the diagnosis of bacterial vaginosis. J Clin Microbiol (1990) 2.22
Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother (2000) 2.22
Streptococcal toxic shock syndrome in dogs. J Am Vet Med Assoc (1996) 2.11
Clinical significance of a test for slime production in ventriculoperitoneal shunt infections caused by coagulase-negative staphylococci. J Infect Dis (1987) 2.10
Use of the polymerase chain reaction for the detection of Chlamydia trachomatis from endocervical and urine specimens in an asymptomatic low-prevalence population of women. Diagn Microbiol Infect Dis (1994) 2.09
Problems with rapid agglutination methods for identification of Staphylococcus aureus when Staphylococcus saprophyticus is being tested. J Clin Microbiol (1988) 2.09
Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis (1993) 2.07
Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada. Antimicrob Agents Chemother (1999) 2.01
The gastroesophageal flap valve: in vitro and in vivo observations. Gastrointest Endosc (1996) 1.97
Rapid selection of complement-inhibiting protein variants in group A Streptococcus epidemic waves. Nat Med (1999) 1.92
Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group. Pediatrics (2000) 1.91
Methicillin-resistant Staphylococcus aureus in horses at a veterinary teaching hospital: frequency, characterization, and association with clinical disease. J Vet Intern Med (2006) 1.91
A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Antimicrob Agents Chemother (2000) 1.89
Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project. J Infect Dis (1995) 1.88
Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis (1998) 1.83
Streptococcus iniae, a human and animal pathogen: specific identification by the chaperonin 60 gene identification method. J Clin Microbiol (1998) 1.75
Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Canadian Bacterial Surveillance Network. Antimicrob Agents Chemother (1996) 1.74
Suspected transmission of methicillin-resistant Staphylococcus aureus between domestic pets and humans in veterinary clinics and in the household. Vet Microbiol (2006) 1.69
Susceptibility testing of clinical isolates of Enterococcus faecium and Enterococcus faecalis. J Clin Microbiol (1992) 1.67
Evaluation of commercial and standard methodology for determination of oxacillin susceptibility in Staphylococcus aureus. J Clin Microbiol (1992) 1.62
Species identification of enterococci via intergenic ribosomal PCR. J Clin Microbiol (1997) 1.61
Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1990) 1.59
Hospital-acquired invasive group a streptococcal infections in Ontario, Canada, 1992-2000. Clin Infect Dis (2005) 1.54
Identification and characterization of multiple species of vancomycin-resistant enterococci, including an evaluation of Vitek software version 7.1. J Clin Microbiol (1993) 1.52
An outbreak of methicillin-resistant Staphylococcus aureus skin infections resulting from horse to human transmission in a veterinary hospital. Vet Microbiol (2005) 1.50
Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study. The Canadian Respiratory Infection Study Group. Antimicrob Agents Chemother (1999) 1.49
Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006. J Clin Microbiol (2008) 1.47
Soft-tissue images. Ecthyma gangrenosum: a deceptively benign skin lesion in febrile neutropenia. Can J Surg (2001) 1.45
Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine (2010) 1.40
Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother (2002) 1.37
Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect Immun (1999) 1.36
Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis (2006) 1.34
Plasmid comparison and molecular analysis of Klebsiella pneumoniae harbouring bla(KPC) from New York City and Toronto. J Antimicrob Chemother (2011) 1.33
Comparison of the new MicroScan Pos MIC Type 6 panel and AMS-Vitek Gram Positive Susceptibility Card (GPS-TA) for detection of high-level aminoglycoside resistance in Enterococcus species. J Clin Microbiol (1991) 1.30
Streptococcus iniae virulence is associated with a distinct genetic profile. Infect Immun (2001) 1.30
Antimicrobial treatment options in the management of odontogenic infections. J Can Dent Assoc (1998) 1.29
Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn Microbiol Infect Dis (1999) 1.28
Canine streptococcal toxic shock syndrome in Ontario: An emerging disease? Can Vet J (1995) 1.28
Reciprocal, temporal expression of SpeA and SpeB by invasive M1T1 group a streptococcal isolates in vivo. Infect Immun (2001) 1.27
Expression and characterization of group A Streptococcus extracellular cysteine protease recombinant mutant proteins and documentation of seroconversion during human invasive disease episodes. Infect Immun (1998) 1.27
Comparison of the Clearview Chlamydia test, Chlamydiazyme, and cell culture for detection of Chlamydia trachomatis in women with a low prevalence of infection. J Clin Microbiol (1991) 1.27
Evaluation of a commercial microtiter system (MicroScan) using both frozen and freeze-dried panels for detection of high-level aminoglycoside resistance in Enterococcus spp. J Clin Microbiol (1990) 1.27
Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. Eur J Immunol (2000) 1.27
The use of Streptococcus pneumoniae nasopharyngeal isolates from healthy children to predict features of invasive disease. Pediatr Infect Dis J (1998) 1.26
Efficacy of microbial identification system for epidemiologic typing of coagulase-negative staphylococci. J Clin Microbiol (1994) 1.26
Streptococcal erythrogenic toxin genes: detection by polymerase chain reaction and association with disease in strains isolated in Canada from 1940 to 1991. J Clin Microbiol (1992) 1.25
Decreased prevalence of virulence factors among ciprofloxacin-resistant uropathogenic Escherichia coli isolates. J Clin Microbiol (2005) 1.25
Phenotypic and genotypic characterization of macrolide-resistant group A Streptococcus strains in the province of Quebec, Canada. J Antimicrob Chemother (2001) 1.25
In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada. Antimicrob Agents Chemother (1999) 1.25
Antibody to cytotoxin in infection by Helicobacter pylori. J Clin Microbiol (1990) 1.24
Group C streptococcal meningitis in an adult. Probable acquistion from a horse. Arch Intern Med (1980) 1.23
Evidence for superantigen involvement in severe group a streptococcal tissue infections. J Infect Dis (2001) 1.23
Low-level colonization of hospitalized patients with methicillin-resistant coagulase-negative staphylococci and emergence of the organisms during surgical antimicrobial prophylaxis. Antimicrob Agents Chemother (1988) 1.23
Broth microdilution testing of Haemophilus influenzae with haemophilus test medium versus lysed horse blood broth. Canadian Haemophilus Study Group. J Clin Microbiol (1992) 1.21
RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci. Diagn Microbiol Infect Dis (1993) 1.20
Practical approach to the identification of clinically relevant Enterococcus species. Diagn Microbiol Infect Dis (1999) 1.20
Evaluation of three methods for the rapid identification of Staphylococcus aureus in blood cultures. Diagn Microbiol Infect Dis (1994) 1.19
Human immune response to streptococcal inhibitor of complement, a serotype M1 group A Streptococcus extracellular protein involved in epidemics. J Infect Dis (2000) 1.17
Strategies for stemming the tide of antimicrobial resistance. JAMA (1998) 1.15
How long should catheter-acquired urinary tract infection in women be treated? A randomized controlled study. Ann Intern Med (1991) 1.15
The prevalence of Campylobacter pylori gastritis among asymptomatic adults. CMAJ (1989) 1.14
In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob Agents Chemother (1995) 1.12
Coagulase-negative staphylococci as true pathogens in newborn infants: a cohort study. Pediatr Infect Dis J (1987) 1.12
Survey of Bacteroides fragilis group susceptibility patterns in Canada. Antimicrob Agents Chemother (1992) 1.12
Annualized incidence and spectrum of illness from an outbreak investigation of Bell's palsy. Neuroepidemiology (2002) 1.11
Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens. Antimicrob Agents Chemother (1990) 1.11
Characterization of a widespread strain of methicillin-susceptible Staphylococcus aureus associated with nosocomial infections. J Infect Dis (1990) 1.10
Group B streptococcal necrotizing fasciitis and streptococcal toxic shock-like syndrome in adults. Arch Intern Med (1998) 1.07
Direct esophageal metastasis from a distant primary tumor is a submucosal process: a review of six cases. Dis Esophagus (2001) 1.07
A cross-Canada surveillance of antimicrobial resistance in respiratory tract pathogens. Can J Infect Dis (1999) 1.07
A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis (2001) 1.07
Use of molecular typing to study the epidemiology of Serratia marcescens. J Clin Microbiol (1990) 1.07
Tracheal rupture with disposable polyvinylchloride double-lumen endotracheal tubes. J Cardiothorac Vasc Anesth (1992) 1.06
Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (2001) 1.06
Impact of antibiotic administrative restrictions on trends in antibiotic resistance. Can J Public Health (2006) 1.05
Epidemiology of needlestick injuries in house officers. J Infect Dis (1990) 1.05
Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J (2004) 1.04